Investor Presentation
Brisbane, Oct 18, 2017 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors this week by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.
The presentation highlights the Company's key achievements and recent commercial activities:
- Current negotiations with #1 global animal health company, Zoetis Inc, regarding a commercial agreement for the worldwide development, distribution and marketing of Detach(R)
- Submission of the Company's dossier to the Australian Pesticides and Veterinary Medicines Authority (APVMA), seeking regulatory approval to register Detach(R) for commercial marketing in Australia
- Preparing Detach(R) for commercial launch in the Australian market
- Revenue up 12.6% to $3.2 million, including the receipt of milestone payments under the Zoetis Research Evaluation and License Option Agreement, receipt of the 2015-16 R&D tax rebate and successful grant funding applications
The presentation also includes a status update on the Company's efforts to develop its product pipeline, extending from its core application to control diarrhoea in pigs, to human gastrointestinal conditions such as Irritable Bowel Syndrome, Inflammatory Bowel Disease and Traveller's Diarrhoea.
To view the presentation, please visit:
http://abnnewswire.net/lnk/6F152097
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
